Prelude Therapeutics (PRLD.US) once surged 28%! Reached clinical trial cooperation and supply agreement with Merck (MRK.US).
Recently, Prelude Therapeutics has reached a clinical trial cooperation and supply agreement with Merck.
Prelude, Merck Strike Clinical Trial Collaboration and Supply Pact
Express News | Prelude Therapeutics- Co, Merck Each Retain All Commercial Rights to Their Respective Compounds, Including as Monotherapy or as Combination Therapies
Express News | Prelude Therapeutics Inc - Expects to Conclude Monotherapy Dose Escalation Mid-2024 and Identify Recommended Phase 2 Dose
Express News | Prelude Therapeutics Inc - Prelude Will Sponsor Clinical Trial and Merck Will Provide Keytruda.
Express News | Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Barclays Cuts Prelude to Underweight, Cites Lack of Near-term Catalysts
Barclays Downgrades Prelude Therapeutics(PRLD.US) to Sell Rating, Maintains Target Price $3
Barclays analyst Peter Lawson downgrades $Prelude Therapeutics(PRLD.US)$ to a sell rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 40.9% and
Express News | Prelude Therapeutics Inc : Barclays Cuts to Underweight From Equal-Weight
The Prelude Network Celebrates Pride 2024 With Educational Events on LGBTQ+ Family Building
The global campaign, Fertility Care for Everyone, continues its second year and includes LGBTQ+ family building virtual events hosted by a panel of esteemed Prelude physicians HOUSTON, June 7, 2024 /
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming
Prelude Therapeutics Files for $400 Million Mixed Shelf
Prelude Therapeutics (PRLD) filed Thursday a registration statement covering the potential sale of up to $400 million of securities from time to time. The securities include common stock, preferred st
Express News | Prelude Therapeutics Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects
Prelude Therapeutics | 10-Q: Quarterly report
Express News | Prelude Therapeutics Inc - Current Cash Runway Into 2026
Express News | Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Express News | Prelude Therapeutics Q1 Net Income USD -31.431 Million